MedTrace Logo

The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

NCT00503698 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 712

Last updated 2017-03-07

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Africa, Asia, Europe, North and South America and Oceania.

The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.

Conditions

Interventions

DRUG

somatropin

20 mcg/kg/day, injected s.c. (under the skin)

DRUG

placebo

Placebo injected s.c (under the skin)

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • China
  • Denmark
  • France
  • Germany
  • Hungary
  • India
  • Israel
  • Italy
  • Poland
  • Portugal
  • Puerto Rico
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00503698 on ClinicalTrials.gov